Tolvaptan in ADPKD Patients With Very Low Kidney Function

INTRODUCTION: Tolvaptan slowed estimated glomerular filtration rate (eGFR) decline in subjects with autosomal dominant polycystic kidney disease (ADPKD) in TEMPO 3:4 and REPRISE trials. Tolvaptan effects in subjects with eGFR 15 to 24 ml/min per 1.73 m(2) were not investigated. This post hoc analysi...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, Vicente E., Gansevoort, Ron T., Perrone, Ronald D., Chapman, Arlene B., Ouyang, John, Lee, Jennifer, Japes, Hina, Nourbakhsh, Ali, Wang, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343715/
https://www.ncbi.nlm.nih.gov/pubmed/34386666
http://dx.doi.org/10.1016/j.ekir.2021.05.037

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8343715/
https://www.ncbi.nlm.nih.gov/pubmed/34386666
http://dx.doi.org/10.1016/j.ekir.2021.05.037

Ejemplares similares